Paris, 17 may 2017 – Truffle Capital, a major player in the european venture capital whose mission is to support the creation and development of innovative young companies, today announced the final completion of the acquisition of Symetis, a leader in the field of cardiac valves by way of mini-invasive (TAVI), by the group Boston Scientific (http://news.bostonscientific.com/2017-05-16-Boston-Scientific-Closes-Symetis-Acquisition) for an amount of 435 million dollars.
Download the free guide
Boost your gains
Truffle Capital is investor of Symetis since its inception and has been involved in all phases of R&D, clinical development, industrialization, CE marking, and marketing in Europe (recording a turnover of 35 million euros in 2016). Boston Scientific is a global leader in the field of medical devices, especially in cardiology.
Truffle Capital is also a co-founder and shareholder in the cardiovascular field of Carmat (artificial heart), Epygon (mitral valve), Kephalios (ring mitral adjustable), Kardiosis (stent graft for aortic aneurysms) ; orthopedics Vexim (implant SpineJack® for vertebral fractures) ; in urology of Myopowers (artificial sphincter) and Théraclion ultrasound interventional.
About Truffle Capital
Truffle Capital is a management company european independent founded in 2001 by Henri Moulard, Philippe Pouletty and Bernard-Louis Roques. Truffle Capital is now headed by Patrick Kron, chairman, alongside co-founder Philippe Pouletty and Bernard-Louis Roques, general managers. Truffle Capital account 750M under management or board, through FCIC, FPIC, holding leaders and management under mandate. Truffle is specialized in investing in companies developing technologies and products of the rupture in the sectors of digital technologies and life sciences. For more information, visit www.truffle.fr
Download the free guide
Boost your gains
